Nathan Sadeghi-Nejad

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza┬┐s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Recent Articles By The Author

A Buysider's Preview of Biotech's Biggest Conference

A Buysider's Preview of Biotech's Biggest Conference

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

Breaking Up With Gilead Sciences

Breaking Up With Gilead Sciences

Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.

Time For Common Sense Gun Control Has Arrived

Time For Common Sense Gun Control Has Arrived

The tragedy in Newtown should bring gun owners and opponents together.

Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing

Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing

Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.

Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

Medical innovation is increasing but ever-escalating drug prices aren't sustainable.

Nate Sadeghi's 2012 Biotech Stock Report Card

Nate Sadeghi's 2012 Biotech Stock Report Card

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

Seattle Genetics: A Short Thesis That's Been Right And Wrong

Seattle Genetics: A Short Thesis That's Been Right And Wrong

Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.

Arena Pharma Is Still A Good Short

Arena Pharma Is Still A Good Short

A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.

Achillion Pharma Worthy of New Look

Achillion Pharma Worthy of New Look

The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.

United Therapeutics Could Lose The Battle For PAH Therapies

United Therapeutics Could Lose The Battle For PAH Therapies

An FDA decision expected this week could easily go against United Therapeutics.